Clinical Policy: House Dust Mite Allergen Extract (Odactra)
Reference Number: ERX.NPA.47
Effective Date: 09.01.17
Last Review Date: 08.20
Line of Business: Commercial, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
House dust mite (Dermatophagoides farinae and Dermatophagoides pteronyssinus) allergen extract (Odactra™) is an allergen extract.

FDA Approved Indication(s)
Odactra is indicated as immunotherapy for house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites, or skin testing to licensed HDM allergen extracts. Odactra is approved for use in adults 18 through 65 years of age.

Odactra is not indicated for the immediate relief of allergy symptoms.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary.

It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Odactra is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Allergic Rhinitis (must meet all):
      1. Diagnosis of HDM-induced allergic rhinitis;
      2. Prescribed by or in consultation with an allergist or immunologist;
      3. Age ≥ 18 years and ≤ 65 years;
      4. Confirmation of the presence of IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus HDM or skin testing to licensed HDM allergen extracts;
      5. Failure of one intranasal corticosteroid, unless clinically significant adverse effects are experienced or all are contraindicated;
      6. Failure of one oral antihistamine at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated;
      7. Dose does not exceed one tablet per day.
   Approval duration: 12 months

B. Other diagnoses/indications
   1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

II. Continued Therapy
   A. Allergic Rhinitis (must meet all):
      1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria;
      2. Member is responding positively to therapy;
      3. If request is for a dose increase, new dose does not exceed one tablet per day.
 Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):
   1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy. 
      Approval duration: Duration of request or 12 months (whichever is less); or 
   2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
FDA: Food and Drug Administration
HDM: house dust mite

Appendix B: Therapeutic Alternatives
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>cetirizine (Zyrtec®)</td>
<td>2 to 5 years: 2.5-5 mg PO QD ≥ 6 years: 10 mg PO QD</td>
<td>10 mg/day</td>
</tr>
<tr>
<td>desloratadine (Clarinex®)</td>
<td>2 to 5 years: 1.25 mg PO QD 6 to 11 years: 2.5 mg PO QD ≥ 12 years: 5 mg PO QD</td>
<td>5 mg/day</td>
</tr>
<tr>
<td>levocetirizine (Xyzal®)</td>
<td>6 to 11 years: 2.5 mg PO QD ≥ 12 years: 5 mg PO QD</td>
<td>5 mg/day</td>
</tr>
<tr>
<td>budesonide (Rhinocort® Aqua)</td>
<td>6 to 11 years: 1-2 sprays each nostril QD ≥ 12 years: 1-4 sprays each nostril QD</td>
<td>4 sprays each nostril/day</td>
</tr>
<tr>
<td>fexofenadine (Allegra Allergy®)</td>
<td>6-months to 2 years: 15 mg PO QD 2 to 11 years: 30 mg PO QD ≥ 12 years: 60 mg PO BID or 180 mg PO QD</td>
<td>180 mg/day</td>
</tr>
<tr>
<td>fluticasone propionate (Flnase®)</td>
<td>≥ 4 years: 1-2 sprays each nostril QD ≥ 12 years: 1-2 sprays each nostril QD</td>
<td>2 sprays each nostril/day</td>
</tr>
<tr>
<td>triamcinolone acetonide (Nasacort AQ®)</td>
<td>2-11 years: 1 spray each nostril QD ≥ 12 years: 1-2 sprays each nostril QD</td>
<td>2-11 years: 1 spray each nostril/day &gt; 12 years: 2 sprays each nostril/day</td>
</tr>
<tr>
<td>mometasone furoate monohydrate (Nasonex®)</td>
<td>2-11 years: 1 spray each nostril QD ≥ 12 years: 2 sprays each nostril QD</td>
<td>2-11 years: 1 spray each nostril/day &gt; 12 years: 2 sprays each nostril/day</td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings
- Contraindication(s): severe, unstable or uncontrolled asthma; history of eosinophilic esophagitis; history of any severe systemic allergic reaction or any severe local reaction to sublingual allergen immunotherapy; hypersensitivity to any of the inactive ingredients contained in this product
- Boxed warning(s): severe allergic reactions
V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>HDM-induced allergic rhinitis</td>
<td>One tablet SL QD</td>
<td>1 tablet/day</td>
</tr>
</tbody>
</table>

VI. Product Availability

Tablet: 12 SQ-HDM

VII. References


<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy created.</td>
<td>03.17</td>
<td>08.17</td>
</tr>
<tr>
<td>3Q 2018 annual review: no significant changes; age added; references reviewed and updated.</td>
<td>04.03.18</td>
<td>08.18</td>
</tr>
<tr>
<td>3Q 2019 annual review: no significant changes; corrected age restriction from &lt; 65 years to ≤ 65 years per PI; references reviewed and updated.</td>
<td>04.22.19</td>
<td>08.19</td>
</tr>
<tr>
<td>3Q 2020 annual review: no significant changes; references reviewed and updated.</td>
<td>04.06.20</td>
<td>08.20</td>
</tr>
</tbody>
</table>

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to

Page 3 of 4